Security
Artelo Biosciences, Inc. Warrant 10/14/2025 · ATLEW
ATLEWOTCWarrantHistorical · closed Oct 14, 2025CIK 1621221Updated Oct 12, 2026
Name history
REACTIVE MEDICAL INC. · through Apr 17, 2017KNIGHT KNOX DEVELOPMENT CORP. · through Feb 6, 2017
Current security for this SEC filerARTL · NASDAQ
ATLEW price & chart
Historical security
This listing closed Oct 14, 2025. Live provider charts are shown only for current listings.
Current security: ARTL
About the company
We are currently developing a novel, benzimidazole dual cannabinoid (CB) agonist that targets both the CB1 and CB2 peripheral receptors. This synthetic small molecule program is a G protein-coupled receptor (“GPCR”) designated ART27.13 and was initially developed by AstraZeneca plc. We are developing ART27.13 as a potential treatment for cancer-related anorexia and it is currently in a Phase 1b/2a trial, titled the Cancer Appetite Recovery Study (“CAReS”). In an interim analysis of the on-going Phase 2a CAReS trial, patients with cancer anorexia receiving ART27.13 demonstrated a mean weight gain of over 6% compared to a 5% loss in the placebo group, while maintaining a safety profile similar to the Phase 1b despite doses up to twice the previous maximum. Currently there is no FDA approved treatment for cancer anorexia cachexia syndrome.
In the news
No coverage from other publishers is available.
Recent filings
Other Events
Items 8.01
Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD Disclosure
Items 3.03, 5.03, 7.01, 9.01
10-Q/A filing
10-Q filing
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | — | — | — | — | — | 2,801,000Source | 4,698,000Source | 13,043,000Source | 2,801,000Source | 4,698,000Source | 13,043,000Source | 20,424,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | — | — | — | 2,039,000Source | 2,039,000Source | 2,039,000Source | 2,039,000Source | 2,039,000Source | 2,039,000Source | 2,039,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | — | 4,198,000Source | — | — | — | — | — | 600,000Source | — | — | 6,888,000Source |
| Assets, CurrentUSD | — | — | — | — | — | 695,000Source | 2,557,000Source | 10,980,000Source | 695,000Source | 2,557,000Source | 10,980,000Source | 18,322,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | — | — | — | — | 95,000Source | 219,000Source | 554,000Source | 95,000Source | 219,000Source | 554,000Source | — |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | — | — | 64,000Source | 99,000Source | 21,000Source | 64,000Source | 99,000Source | 21,000Source | 60,000Source |
| Other Assets, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 3,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | — | — | — | — | — | 4,073,000Source | 1,841,000Source | 1,291,000Source | 4,073,000Source | 1,841,000Source | 1,291,000Source | 1,021,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | — | — | — | — | — | 1,000Source | 3,000Source | 3,000Source | 2,000Source | 3,000Source | 3,000Source | 3,000Source |
| Additional Paid in CapitalUSD | — | — | — | — | — | 62,014,000Source | 53,192,000Source | 52,262,000Source | 62,013,000Source | 53,192,000Source | 52,262,000Source | 50,675,000Source |
| Retained Earnings (Accumulated Deficit)USD | — | — | — | — | — | -63,015,000Source | -50,136,000Source | -40,310,000Source | -63,015,000Source | -50,136,000Source | -40,310,000Source | -31,021,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | — | — | — | -272,000Source | -202,000Source | -203,000Source | -272,000Source | -202,000Source | -203,000Source | -254,000Source |
| Stockholders' Equity Attributable to ParentUSD | -1,406,000Source | 7,299,000Source | 6,672,000Source | 652,000Source | 9,537,000Source | -1,272,000Source | 2,857,000Source | 11,752,000Source | -1,272,000Source | 2,857,000Source | 11,752,000Source | 19,403,000Source |
| Liabilities and EquityUSD | — | — | — | — | — | 2,801,000Source | 4,698,000Source | 13,043,000Source | 2,801,000Source | 4,698,000Source | 13,043,000Source | 20,424,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | — | — | — | — | — | 4,044,000Source | 1,772,000Source | 1,291,000Source | 4,044,000Source | 1,772,000Source | 1,291,000Source | 998,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | — | — | 40,000Source | 35,000Source | 23,000Source | 40,000Source | 35,000Source | 23,000Source | 40,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | — | — | 29,000Source | 69,000Source | — | 29,000Source | 69,000Source | 0Source | 23,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | — | — | — | — | 11,000Source | — | — | 11,000Source | — | — | — |
cash flow · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -2,958,000Source | -2,372,000Source | — | — | — | — | — | -9,826,000Source | — | 10,083,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 150,000Source | 195,000Source | — | 192,000Source | 213,000Source | — | — | — | 1,142,000Source | 818,000Source | 1,020,000Source | 2,458,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | — | — | -8,520,000Source | -8,350,000Source | -8,207,000Source | -8,008,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | -62,000Source | 7,769,000Source | 3,507,000Source | 2,958,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | — | 6,867,000Source | 112,000Source | 567,000Source | 0Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | — | -1,738,000Source | -477,000Source | -4,073,000Source | -5,274,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | 600,000Source | 2,338,000Source | 2,815,000Source | 600,000Source | 2,338,000Source | 2,815,000Source | 6,888,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | — | — | -23,000Source | -8,000Source | 60,000Source | -224,000Source |
| Additional Financial Items | ||||||||||||
| Amortization of Deferred ChargesUSD | — | — | — | — | — | — | — | — | 209,000Source | — | — | — |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | — | — | — | — | — | — | -62,000Source | — | — | — |
| Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | 22,000Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | -825,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | 5,981,000Source | 4,115,000Source | 4,234,000Source | 5,963,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -3,221,000Source | -2,433,000Source | — | -2,372,000Source | -2,483,000Source | — | — | — | -12,879,000Source | -9,826,000Source | -9,289,000Source | -10,083,000Source |
| Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | -1,475,000Source | 282,000Source | 641,000Source | 204,000Source |
| Operating ExpensesUSD | — | — | — | — | — | — | — | — | 11,404,000Source | 10,108,000Source | 9,930,000Source | 10,287,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 6,151,000Source | 112,000Source | 567,000Source | 0Source |
income statement · annual statements
| Line item | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | — | — | — | — | — | — | -11,404,000Source | -10,108,000Source | -9,930,000Source | -10,287,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -3,221,000Source | -2,433,000Source | -1,599,000Source | -2,449,000Source | -2,372,000Source | -2,483,000Source | -2,168,000Source | -1,965,000Source | -12,879,000Source | -9,826,000Source | -9,289,000Source | -10,083,000Source |
| Earnings Per Share, DilutedUSD per share | — | — | — | — | — | — | — | — | -12.52Source | -3.05Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | — | — | — | — | — | 1,029,000Source | 3,223,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | 22,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | 5,981,000Source | 4,115,000Source | 4,234,000Source | 5,963,000Source |
| Interest and Other IncomeUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 2,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | 194,000Source | — | 0Source | 5,000Source |
| Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | -1,475,000Source | 282,000Source | 641,000Source | 204,000Source |
| Operating ExpensesUSD | — | — | — | — | — | — | — | — | 11,404,000Source | 10,108,000Source | 9,930,000Source | 10,287,000Source |
| Research and Development ExpenseUSD | — | — | — | — | — | — | — | — | 5,423,000Source | 5,993,000Source | 5,696,000Source | 4,324,000Source |
Offerings
Registration 333-295537
Registration 333-294912
Registration 333-294506
Registration 333-294579
Filing attachments
artl_ex991.htm · 8-K · 2026-08-27
EX-99.1 3 artl_ex991.htm PRESS RELEASE artl_ex991.htm EXHIBIT 99.1 Artelo Biosciences Announces Reverse Stock Split Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026 SOLANA BEACH, CA - August 27, 2026 - Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, to…
Read attachment ↗artl_ex43.htm · S-3/A · 2026-05-14
EXHIBIT 4.3 ARTELO BIOSCIENCES, INC. ______________ INDENTURE Dated as of ________________ ______________ [__________] Trustee TABLE OF CONTENTS ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE. 6 Section 1.1 Definitions. 6 Section 1.2 Incorporation by Reference of Trust Indenture Act. 8 Section 1.3 Rules of Construction. …
Read attachment ↗artl_ex107.htm · S-3 · 2026-05-04
EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Artelo Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Security Notes Fee Amount Proposed Maximum Offering Maximum Fee Amount of Carry Forward Form Type Carry Forward File Number Ca…
Read attachment ↗artl_ex991.htm · 8-K · 2026-04-07
EX-99.1 2 artl_ex991.htm PRESS RELEASE artl_ex991.htm EXHIBIT 99.1 Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements Nasdaq confirms Company has regained compliance with Listing Rules 5550(b)(1) and 5620(a) SOLANA BEACH, Calif., April 7, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical‑stage pharmaceutical company focused on modulating lipid‑signaling pathways to develop treatments for people living with cancer, pain, dermatological, or ne…
Read attachment ↗artl_ex41.htm · 8-K · 2026-03-30
EX-4.1 2 artl_ex41.htm FORM OF PRE-FUNDED WARRANT artl_ex41.htm EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECU…
Read attachment ↗artl_ex42.htm · 8-K · 2026-03-30
EX-4.2 3 artl_ex42.htm FORM OF COMMON WARRANT artl_ex42.htm EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITI…
Read attachment ↗